Particularly, compared to all different types of BC, the treatment of triple-negative breast cancer (TNBC), a subtype of BC that does not express estrogen and progesterone receptors (ER and PR) and does not overexpress HER-2, remains highly challenging due to the aggressive nature of the disease and limited responses to therapies. The gene discussed is ERBB2; the disease is breast cancer.